Using data from the phase 3 CM 649 trial in patients with HER2-negative, advanced GC/GEJC/EAC, this post hoc analysis found a statistically significant gain in quality-adjusted survival by 1.8 (95% CI 0.9, 2.7) months when NIVO + chemo was compared with chemo alone in previously untreated patients with advanced GC/GEJC/EAC. Here, ERBB2 is linked to gastric cancer.